Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jan;40(1):212–214. doi: 10.1128/aac.40.1.212

In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.

L Welsh 1, C Gaydos 1, T C Quinn 1
PMCID: PMC163084  PMID: 8787907

Abstract

Thirteen strains of Chlamydia pneumoniae were evaluated for their in vitro susceptibilities to azithromycin, clarithromycin, erythromycin, and tetracycline. The MIC ranges were 0.125 to 0.5 micrograms/ml for azithromycin, 0.031 to 1.0 micrograms/ml for clarithromycin, 0.125 to 1.0 micrograms/ml for erythromycin, and 0.25 to 1.0 micrograms/ml for tetracycline. The ranges for the minimal lethal concentrations were 0.125 to 0.5 micrograms/ml for azithromycin, 0.031 to 1.0 micrograms/ml for clarithromycin, 0.125 to 1.0 micrograms/ml for erythromycin, and 0.25 to 1.0 micrograms/ml for tetracycline. Clarithromycin and azithromycin were the most active antibiotics against C. pneumoniae in vitro.

Full Text

The Full Text of this article is available as a PDF (160.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin D. R., Wise R., Andrews J. M., Ashby J. P., Honeybourne D. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J. 1990 Sep;3(8):886–890. [PubMed] [Google Scholar]
  2. Block S., Hedrick J., Hammerschlag M. R., Cassell G. H., Craft J. C. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J. 1995 Jun;14(6):471–477. doi: 10.1097/00006454-199506000-00002. [DOI] [PubMed] [Google Scholar]
  3. Chirgwin K., Roblin P. M., Hammerschlag M. R. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob Agents Chemother. 1989 Sep;33(9):1634–1635. doi: 10.1128/aac.33.9.1634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fraschini F., Scaglione F., Pintucci G., Maccarinelli G., Dugnani S., Demartini G. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):61–65. doi: 10.1093/jac/27.suppl_a.61. [DOI] [PubMed] [Google Scholar]
  5. Grayston J. T., Campbell L. A., Kuo C. C., Mordhorst C. H., Saikku P., Thom D. H., Wang S. P. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990 Apr;161(4):618–625. doi: 10.1093/infdis/161.4.618. [DOI] [PubMed] [Google Scholar]
  6. Grayston J. T., Kuo C. C., Wang S. P., Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986 Jul 17;315(3):161–168. doi: 10.1056/NEJM198607173150305. [DOI] [PubMed] [Google Scholar]
  7. Hammerschlag M. R. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother. 1994 Sep;38(9):1873–1878. doi: 10.1128/aac.38.9.1873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mourad A., Sweet R. L., Sugg N., Schachter J. Relative resistance to erythromycin in Chlamydia trachomatis. Antimicrob Agents Chemother. 1980 Nov;18(5):696–698. doi: 10.1128/aac.18.5.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mundy L. M., Auwaerter P. G., Oldach D., Warner M. L., Burton A., Vance E., Gaydos C. A., Joseph J. M., Gopalan R., Moore R. D. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1309–1315. doi: 10.1164/ajrccm.152.4.7551387. [DOI] [PubMed] [Google Scholar]
  10. Roblin P. M., Montalban G., Hammerschlag M. R. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother. 1994 Jul;38(7):1588–1589. doi: 10.1128/aac.38.7.1588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rodvold K. A., Piscitelli S. C. New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety. Clin Infect Dis. 1993 Aug;17 (Suppl 1):S192–S199. doi: 10.1093/clinids/17.supplement_1.s192. [DOI] [PubMed] [Google Scholar]
  12. Walsh M., Kappus E. W., Quinn T. C. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. Antimicrob Agents Chemother. 1987 May;31(5):811–812. doi: 10.1128/aac.31.5.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Welsh L. E., Gaydos C. A., Quinn T. C. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Feb;36(2):291–294. doi: 10.1128/aac.36.2.291. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES